Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer’s Disease

DUBLIN--(BUSINESS WIRE)---- $PRTA #Alzheimers--Prothena announced positive topline Phase 1 SAD study results for PRX005, an investigational tau antibody for the treatment of Alzheimer’s disease.